DelveInsight’s, “Non Muscle Invasive Bladder Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Insight Report
Recent Developmental Activities in the Non-Muscle Invasive Bladder Cancer Pipeline
Request a sample and discover more about the Non-Muscle Invasive Bladder Cancer pipeline report offerings @ Non-Muscle Invasive Bladder Cancer Pipeline Outlook Report
Non-Muscle Invasive Bladder Cancer Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.
Non-Muscle Invasive Bladder Cancer Pipeline Report
In the Non-Muscle Invasive Bladder Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Non-Muscle Invasive Bladder Cancer Emerging Drugs Profile
UGN-102: UroGen Pharma
UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Non Muscle Invasive Bladder Cancer.
Sasanlimab: Pfizer
Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells. PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. Pfizer is developing PF-06801591 for the treatment of Non-muscle Invasive Bladder Cancer and is currently in phase III stage of development.
Find out more about the disease and recent developments in Non-Muscle Invasive Bladder Cancer Pipeline @ Non-Muscle Invasive Bladder Cancer Ongoing Clinical Trials Analysis
Scope of the Non-Muscle Invasive Bladder Cancer Pipeline
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Learn more about the novel and emerging Non-Muscle Invasive Bladder Cancer pipeline therapies @ Non-Muscle Invasive Bladder Cancer Treatment Landscape
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09193216187Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/